 MINNEAPOLIS--BUSINESS WIRE--DiaMedica Therapeutics Inc. Nasdaq: DMAC announced that it recently received written responses from the FDA following a Type B Pre-IND meeting request that the Company submitted in October 2020 regarding the Companys development plan for its product candidate, DM199, in the treatment of acute ischemic stroke AIS. DiaMedica believes that the feedback received from the FDA provides a well-defined regulatory pathway and plans to immediately proceed with preparing 